Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
breast cancer | Research | Treatment | 10 pages | source: The New England Journal of Medicine | Added Jun 05, 2022

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the disease-free survival rates in these patients.

icon
rheumatoid arthritis | Research | 10 pages | source: Arthritis Research & Therapy | Added Jun 01, 2022

Can disease flare be predicted following remission and treatment withdrawal in patients with early rheumatoid arthritis?

This study identified predictors of disease flare in patients with early, active rheumatoid arthritis (RA) that had stopped methotrexate (MTX; Otrexup) and/or abatacept (Orencia) treatment after clinical remission was achieved at 12 months. The data showed that patient function (HAQ-DI) and bone erosion based on magnetic resonance imaging (MRI) scans predicted disease flare at 6 months and 12 months after treatment withdrawal.

icon
breast cancer | Research | 10 pages | source: Frontiers in oncology | Added May 31, 2022

Evaluating the effectiveness of antiresorptive drugs on bone mineral density in postmenopausal women with early-stage breast cancer receiving treatment with aromatase inhibitors.

This study evaluated the effectiveness of antiresorptive drugs on bone mineral density (BMD) in postmenopausal women with early-stage breast cancer (BC) receiving treatment with aromatase inhibitors (AIs). The data showed that denosumab (Prolia) and zoledronic acid (Aclasta) were the most effective antiresorptive treatment options to improve BMD in these patients.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Frontiers in immunology | Added Apr 29, 2022

How effective is denosumab treatment in patients with rheumatoid arthritis?

This review evaluated the effectiveness of denosumab (Prolia) on bone mineral density (BMD) and joint destruction in patients with rheumatoid arthritis (RA). The authors concluded that denosumab treatment was linked to increased BMD and reduced joint destruction in patients with RA.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Apr 03, 2022

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to methotrexate (Otrexup; MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), and those that are MTX-naive (have never received MTX).

icon
breast cancer | Research | 10 pages | source: Frontiers in oncology | Added Mar 20, 2022

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a significantly higher risk of developing ARD while hypofractionated RT reduced the risks of ARD in these patients.

icon
icon
breast cancer | Research | Lifestyle | 10 pages | source: Frontiers in oncology | Added Feb 13, 2022

Evaluating the effects of physical therapies on improvement in psychosomatic symptoms and quality of life in patients with breast cancer treated with aromatase inhibitors.

This study evaluated the effects of physical therapies on improvement in psychosomatic symptoms and quality of life (QoL) in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). The data showed that acupuncture can significantly reduce pain intensity and exercise training might improve QoL in these patients. 

icon
rheumatoid arthritis | Research | 10 pages | source: Annals of the rheumatic diseases | Added Jan 19, 2022

Comparing response to SARS-CoV-2 mRNA vaccine doses for patients with RA and healthy controls.

This study evaluated immune responses after two doses of SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases including rheumatoid arthritis (RA) compared to healthy controls (HCs). The data showed that patients with inflammatory joint diseases had similar responses to mRNA vaccines after 2 doses. 

icon
icon
breast cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jan 09, 2022

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness.

icon
icon
breast cancer | Research | Treatment | 10 pages | source: Nature Medicine | Added Dec 31, 2021

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in these patients.

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?